Resume
Summary Pulmonary Hypertension
- Cours
- Établissement
- Book
A summary of the chapter about Pulmonary Hypertension
[Montrer plus]
Livre connecté
Titre de l’ouvrage:
Auteur(s):
- Édition:
- ISBN:
- Édition:
Plus de résumés pour
-
Cardiovascular Diseases Practice Exam,Harrison's Internal Medicine 21st EEd
-
Test Bank For Harrison s principles of internal medicine self assessment and board review 19 Edition
-
Summary on Hypothyroidism Chapter from Harrison's Principles of Internal Medicine, 21st. ed.
Vendeur
S'abonner
scythelar913
Aperçu du contenu
1 [Harrison’s 21st] 283. Pulmonary HypertensionPulmonary hypertension (PH)
- Heterogenous disease involving pathogenic remodeling of the pulmonary vasculature, which
increases pulmonary artery pressure and vascular resistance
- Left heart or primary lung disease
o Most common cause
- Observed in some patients as a late complication of luminal pulmonary embolism
- Pulmonary arterial hypertension (PAH)
o Uncommon
o Distinct, PH subtype characterized by the interplay between molecular and genetic
events that cause an obliterative arteriopathy and symptoms of dyspnea, chest
pain, and syncope
- If left untreated
o Carries a high mortality rate, largely owing to decompensated right heart failure
- Mean pulmonary artery pressure (mPAP) used to diagnose PH
o Lowered from > 25 mmHg to > 20 mmHg
Adjustment emphasizes earlier detection of PH, as a substantial
delay in diagnosis of up to 2 years is common
Has important implications for both quality of life and life span
PATHOBIOLOGY DIAGNOSIS
- Underlie the pathogenesis of PAH: - Findings often overlooked
Apoptosis resistance - Symptoms are nonspecific, insidious, and overlap considerably with many common conditions
Cell proliferation
Dysregulated metabolism - Present with dyspnea and/or fatigue
Increased oxidant stress involving pulmonary vascular cells and - Less common and associated with more advanced disease:
adventitial fibroblasts o Edema
o Events lead to hypertrophic, fibrotic, and plexogenic remodeling of distal (small) o Chest pain
pulmonary arterioles, which decreases vascular compliance and promotes in situ o Presyncope
thrombosis o Syncope
- Vasoconstriction-dominant phenotype - Early phases of PAH
o Minority of patients o Physical examination is often unrevealing
o Requires a unique treatment strategy
- Disease progresses
- Abnormalities in multiple molecular pathways and genes that regulate pulmonary vascular
o Evidence of right ventricular failure with elevated jugular venous pressure, lower
endothelial and smooth muscles: extremity edema, and ascites
o Decreased expression of the voltage-regulated potassium channel
o Mutations in the bone morphogenetic protein receptor-2 - Cardiovascular examination
o Increased tissue factor expression o May reveal an accentuated P2 component of the second heart sound, a right-sided
o Overactivation of the serotonin transporter S3 or S4, and a holosystolic tricuspid regurgitant murmur
o Hypoxia-induced activation of hypoxia-inducible factor-1a - Seek signs of the diseases that are commonly concurrent PH:
o Activation of nuclear factor of activated T cells o Clubbing
- May amplify the obliterative arteriopathy Seen in some chronic lung diseases
o Thrombin deposition in the pulmonary vasculature that develops as an o Sclerodactyly and telangiectasia
independent abnormality Signify scleroderma or the limited cutaneous for, CREST (calcinosis,
o As a result of endothelial dysfunction Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and
telangiectasia)
o Crackles on examination of the lungs and systemic hypertension
PATHOPHYSIOLOGY May be clues to left-sided systolic or diastolic heart failure
- In PAH:
OVERVIEW OF THE DIAGNOSTIC CLINICAL EVALUATION
o Pathologic changes to pulmonary arterial compliance
Result in a progressive increase in total pulmonary vascular
resistance (PVR) - Electrocardiography
o Right ventricular hypertrophy or stain
- Resting PVR
o Increases through the temporal progression of PAH - Enlargement of pulmonary arteries and obliteration of the retrosternal space
o Often observed on chest roentgenography
- Preserve cardiac output (CO) in the face of elevated right ventricular afterload
o Right ventricular work must increase - Echocardiography with agitated saline (bubble) study
o Most important initial screening test
- Sustained (or progressive) increase in right ventricular work
o Causes a shift in the efficiency of right ventricular systolic function by which - Elevated estimated pulmonary artery systolic pressure (> 35 mmHg) or a hypertrophied or
maintaining pulmonary circulatory pressure depletes myocardial energy dilated right ventricular
Changes occur at the expense of energy normally reserved to o Support the diagnosis of PH
maintain optimal blood perfusion through the alveolar-capillary - Specific etiologies of PH
interface for blood oxygenation o Valvular disease
Right ventricular-pulmonary arterial uncoupling o Left ventricular systolic and diastolic function
- End-stage PAH o Left atrial enlargement
o CO declines, leading to a decrease in mPAP o Intracardiac shunt
o Extravascular manifestations are frequent - Patients with evidence of PH on echocardiography or in whom unexplained dyspnea or
Overactivation of neurohumoral signaling hypoxemia is evident despite an unremarkable echocardiogram
Renal failure o Often require further assessment
Volitional muscle atrophy
Due to deconditioning - Additional tests focusing functional capacity
o Useful for quantifying disease burden
6-minute walk distance (6-MWD) assessment
Aids in assessing prognosis prognosis
- Cardiopulmonary exercise testing (CPET)
o Differentiates between cardiac and pulmonary causes of dyspnea
o Includes:
Measuring peak volume of oxygen consumption
Integrated parameter of cardiopulmonary fitness
Useful in prognosticating PH
o Patients with normal CPET
Further invasive testing is often necessary
Exception:
o Patients with reassuring CPET results
but in whom a significant decrease in
exercise tolerance from baseline is
nonetheless reported
Often observed in elite
athletes or highly
, 2 [Harrison’s 21st] 283. Pulmonary Hypertension
conditioned individuals o Lowers NT-proBNP levels in PAH
with early-stage PH o May be used as a biomarker for assessing treatment response in clinical practice
- Invasive hemodynamic monitoring with right heart catheterization (RHC)
o Gold standard for PH diagnosis and severity assessment
o Interpretation often optimized by information from diagnostic tests that support
and frame the clinical context of pulmonary vascular disease INVASIVE CARDIOPULMONARY HEMODYNAMICS
- RHC
STEPWISE APPROACH TO DIAGNOSING PH o Remains the gold standard test to both establish the diagnosis of PH and guide
selection of appropriate medical therapy
- Patients with a string history of inhaled tobacco use - Hemodynamic criteria for diagnosing PH:
o May benefit from prioritizing diagnostic tests assessing pulmonary function and the o Require an mPAP >20 mmHg
lung parenchyma
- Precapillary and postcapillary PH
- Myocardial ischemia evaluation o Distinguished by virtue of a pulmonary artery wedge pressure (PAWP)(or left
o Should be considered early in the evaluation of patients with left-sided ventricular of a pulmonary artery wedge pressure (LVEDP) < 15 mmHg or > 15
cardiomyopathy mmHg
- Isolated precapillary PH
o Requires a PVR > 3.0 Wood units (WU)
PULMONARY FUNCTION AND LUNG IMAGING
- Isolated postcapillary PH
- Pulmonary function testing results o Defined by PVR <3.0 WU
o May suggest restrictive or obstructive lung diseases as the cause of dyspnea or PH - Combined pre- and postcapillary PH
- PAH o Recognized, defined by elevated mPAP >20 mmHg, PVR > 3.0 WU, and PAWP >15
o Isolated reduction in diffusing capacity of the lungs for carbon monoxide (DL CO) mmHg
Classic finding
- High-resolution computed tomography (CT)
o Provides useful information, particularly enlargement of the main pulmonary
artery, right ventricle, and atria, as well as peripheral pruning of small vessels
o May also reveal signs of venous congestion including centrilobular ground glass
infiltrate and thickened septa
- Absence of left heart disease
o Suggest pulmonary venous disease
Rare cause of PAH that can be quite challenging to diagnose
- CT - Hemodynamic profiles
o Critical for distinguishing co-morbid interstitial lung disease, emphysema, or overlap o Inform PH clinical categorization
syndromes that include fibrosis and obstructive pulmonary disease o Isolated precapillary PH
Most often due to primary lung disease, PAH, or CTEPH
o Isolated postcapillary PH
SLEEP STUDIES Occurs in patients with mitral valvular disease, left ventricular
systolic dysfunction, or heart failure with preserved ejection faction
- Nocturnal desaturation - Same etiologies for isolated postcapillary PH
o Common finding in PH, even in the absence of sleep-disordered breathing o Underlie combined pre and postcapillary PH
- All patients Indicates that chronic vascular congestion due to left atrial
o Should undergo nocturnal oximetry screening, regardless of whether classic hypertension has resulted in substantial pulmonary vascular
symptoms of obstructive sleep apnea or obesity-hypoventilation syndrome are remodeling
present - Vasoreactivity testing
o Should be reserved mainly for patients with idiopathic or hereditary PAH
ASSESSMENT OF PULMONARY ARTERIAL THROMBOSIS - Vasodilators with a short duration of action
Inhaled nitric oxide (NO)
Inhaled epoprostenol
- Patients with prior luminal pulmonary embolism
o Preferred for testing
o Increased risk for chronic thromboembolic pulmonary hypertension (CTEPH)
Specific PH subtype characterized by vascular fibrosis and arterial - Decrease in mPAP by > 10 mmHg to an absolute level <40 mmHg without a decrease in CO
microthrombus o Positive pulmonary vasodilator response
Curable in many patients by surgical endarterectomy Considered for long-term treatment with calcium channel blockers
Widely underdiagnosed - Less than 5% of patients
- Ventilation-perfusion (V/Q) scanning o Deemed vasoreactive
o Primary test used to screen and diagnose CTEPH o Prognosis among these patients is particularly favorable
Should be considered in any patient with PH of unclear etiology
- CT angiography
o Commonly used to stage anatomic thromboembolic burden which may be
PULMONARY HYPERTENSION CLASSIFICATION
ultimately necessary to determine operative candidacy
- Pulmonary angiography
o Definitive diagnostic procedure
o Contrast enhancement in this study provides detailed information on webbing,
stricture, and vascular tapering patterns pathognomonic for CTEPH
SEROLOGY
- Human immunodeficiency virus (HIV) test
o Laboratory data that are important for screening
o When clinically indicated
- All patients - PH clinical classification schema
o Should have antinuclear antibodies, rheumatoid factor, and anti-Scl-70 antibodies o Formulated
assessed to screen for the most common rheumatologic diseases associated with o According to similarities in pathophysiologic mechanisms and clinical presentation
PH - Current classification system
- Liver function and hepatitis serology tests o Last revised in 2018 during the Sixth World Symposium on Pulmonary
o Important to screen for underlying liver disease Hypertension, recognizes five PH categories listed here sequentially as groups 1-5:
PAH
- Methamphetamine use
PH due to left heart disease
o Recognized increasingly as a cause of PAH
PH due to chronic lung disease, or sleep-disordered breathing
- Screening CTEPH
o Should be considered in patients from endemic regions or in whom the cause of Group of miscellaneous diseases that rarely cause PH
PAH is not otherwise established
- Brain natriuretic peptide (BNP) and the N-terminus of its pro-peptide (NT-proBNP)
o Correlate with right ventricular (dys) function, hemodynamic severity, and
PULMONARY ARTERIAL HYPERTENSION
functional status in PAH
- WHO group 1 PH or PAH
- Medical therapy
o Involves marked pulmonary arterial precapillary remodeling including:
Les avantages d'acheter des résumés chez Stuvia:
Qualité garantie par les avis des clients
Les clients de Stuvia ont évalués plus de 700 000 résumés. C'est comme ça que vous savez que vous achetez les meilleurs documents.
L’achat facile et rapide
Vous pouvez payer rapidement avec iDeal, carte de crédit ou Stuvia-crédit pour les résumés. Il n'y a pas d'adhésion nécessaire.
Focus sur l’essentiel
Vos camarades écrivent eux-mêmes les notes d’étude, c’est pourquoi les documents sont toujours fiables et à jour. Cela garantit que vous arrivez rapidement au coeur du matériel.
Foire aux questions
Qu'est-ce que j'obtiens en achetant ce document ?
Vous obtenez un PDF, disponible immédiatement après votre achat. Le document acheté est accessible à tout moment, n'importe où et indéfiniment via votre profil.
Garantie de remboursement : comment ça marche ?
Notre garantie de satisfaction garantit que vous trouverez toujours un document d'étude qui vous convient. Vous remplissez un formulaire et notre équipe du service client s'occupe du reste.
Auprès de qui est-ce que j'achète ce résumé ?
Stuvia est une place de marché. Alors, vous n'achetez donc pas ce document chez nous, mais auprès du vendeur scythelar913. Stuvia facilite les paiements au vendeur.
Est-ce que j'aurai un abonnement?
Non, vous n'achetez ce résumé que pour €8,04. Vous n'êtes lié à rien après votre achat.
Peut-on faire confiance à Stuvia ?
4.6 étoiles sur Google & Trustpilot (+1000 avis)
85443 résumés ont été vendus ces 30 derniers jours
Fondée en 2010, la référence pour acheter des résumés depuis déjà 14 ans